Juliet Tammenoms Bakker net worth and biography

Juliet Bakker Biography and Net Worth

Director of Axonics

Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures, where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Alphaeon, Axonics Modulation Technologies (AXNX), DyaMX, Encore Dermatology, Nalu, RxSight and Venus Concept. She has previously served on the boards of Ablation Frontiers (acquired by Medtronic), AqueSys (acquired by Allergan), CryoVascular Systems (acquired by Boston Scientific), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), and Sadra Medical (acquired by Boston Scientific). Ms. Bakker holds an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University (“CALS”), where she is a member of the CALS Advisory Council. Ms. Bakker is also a board member of the Boys and Girls Club of Greenwich.

What is Juliet Tammenoms Bakker's net worth?: The estimated net worth of Juliet Tammenoms Bakker is at least $1.83 million as of February 12th, 2024. Ms. Bakker owns 25,840 shares of Axonics stock worth more than $1,834,123 as of December 22nd. This net worth estimate does not reflect any other assets that Ms. Bakker may own. Learn More about Juliet Tammenoms Bakker's net worth.
How do I contact Juliet Tammenoms Bakker?: The corporate mailing address for Ms. Bakker and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Juliet Tammenoms Bakker's contact information.
Has Juliet Tammenoms Bakker been buying or selling shares of Axonics?: Juliet Tammenoms Bakker has not been actively trading shares of Axonics within the last three months. Most recently, Bakker Juliet Tammenoms sold 9,167 shares of the business's stock in a transaction on Friday, September 18th. The shares were sold at an average price of $42.67, for a transaction totalling $391,155.89. Following the completion of the sale, the director now directly owns 3,500 shares of the company's stock, valued at $149,345. Learn More on Juliet Tammenoms Bakker's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (Co-Founder, Chief Executive Officer and Director), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 8 times. They sold a total of 92,797 shares worth more than $6,275,226.67. The most recent insider tranaction occured on October, 2nd when CFO Kari Leigh Keese sold 2,961 shares worth more than $205,523.01. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 10/2/2024.

Juliet Tammenoms Bakker Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/18/2020	Sell	9,167	$42.67	$391,155.89	3,500
8/14/2020	Sell	2,393	$43.22	$103,425.46	9,167
11/2/2018	Buy	533,333	$15.00	$7,999,995.00

Juliet Tammenoms Bakker Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $70.98

$70.37

$71.05

50 Day Range

MA: $70.61

$69.66

$70.98

2 Week Range

Now: $70.98

$55.09

$71.05

Volume

4,233,300 shs

Average Volume

713,457 shs

Market Capitalization

$3.63 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol